25 May 2013
Keywords: fosamax, compares, well, against, rivals, findings, new
Article | 19 April 2004
Findings from a new analysis of clinical data for osteoporosis medications show that Merck & Co's Fosamax (alendronate) provides better
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 April 2004
26 April 2004
24 May 2013
© 2013 thepharmaletter.com